Labetalol, a cross-over double blind controlled trial

@article{Sanders1978LabetalolAC,
  title={Labetalol, a cross-over double blind controlled trial},
  author={G. Lawrence Sanders and Philip A Routledge and Jyoti Rao and G. M. Gales and D. Julian M. Davies and Michael D Rawlins},
  journal={European Journal of Clinical Pharmacology},
  year={1978},
  volume={14},
  pages={301-304}
}
20 patients (12 female) with moderately severe essential hypertension [blood pressure during placebo treatment 181±6 (systolic), 107±3 (diastolic)] completed a double-blind, cross-over dosetitrated comparison of labetalol and methyldopa. Both drugs reduced lying and standing arterial blood pressure to a similar extent, although only labetalol reduced heart rate. Compliance was high (>95%) with both drugs, and the incidence of subjective adverse effects was similar. 

2 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Labetalol , a cross - over double blind controlled trial . 20 patients ( 12 female ) with moderately severe essential hypertension [ blood pressure during placebo treatment 181±6 ( systolic ) , 107±3 ( diastolic ) ] completed a double - blind , cross - over dosetitrated comparison of labetalol and methyldopa .
Labetalol , a cross - over double blind controlled trial . 20 patients ( 12 female ) with moderately severe essential hypertension [ blood pressure during placebo treatment 181±6 ( systolic ) , 107±3 ( diastolic ) ] completed a double - blind , cross - over dosetitrated comparison of labetalol and methyldopa .
All Topics